
AsianScientist (May 28, 2014) – Astellas Pharma Inc’s androgen receptor signaling inhibitor, XTANDI® is now available for the treatment of patients with castration-resistant prostate cancer in Japan.
XTANDI® is an oral, once-daily, androgen receptor signaling inhibitor. It inhibits multiple steps in the androgen receptor signaling pathway, which has been shown to decrease cancer cell growth and can induce cancer cell death.
XTANDI® (generic name: enzalutamide) is being jointly developed and commercialized with US-based company, Medivation Inc. It has previously obtained approval in Europe and the US for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received the chemotherapy drug docetaxel.
Astellas and Medivation are collaborating on a comprehensive development program that includes studies to develop enzalutamide across the full spectrum of advanced prostate cancer as well as advanced breast cancer. Astellas has the responsibility of manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI® outside the United States.
—–
Source: Astellas Pharma Inc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.